NEW YORK – March 25, 2020 – Signals Analytics, the next-generation advanced analytics platform that leverages external data to uncover trends and predictive insights, today unveils its COVID-19 Playbook, providing access to critical market intelligence and trends surrounding potential treatments for the novel coronavirus. As part of their dedication to fighting the virus, Signals Analytics is offering the COVID-19 Playbook at no cost to researchers looking to monitor vaccines that are in development for COVID-19 and other strains of coronavirus; monitor trending drugs that are being tested for COVID-19; and assess which drugs are being repurposed to help treat infected people.
The COVID-19 Playbook is a front-end user interface of the Signals Analytics platform, powered by advanced analytics, patented Natural Language Processing (NLP) techniques and taxonomies developed by domain experts with years of academic and pharmaceutical industry experience. It connects data from a wide range of sources including clinical trials, research papers, business events, announcements, media coverage, drug developments and more. Context is extracted from the various data types and visualizations and actionable insights are generated.
Like Signals Analytics’ other playbooks, the COVID-19 Playbook is aimed at heads of research, development, and innovation as well as leaders responsible for growth, business development, mergers and acquisitions, looking for ways to speed up the vaccine and drug discovery process. The aggregated dashboards address many important business questions such as: what are the leading and emerging targets being analyzed for COVID-19, which are the leading and emerging drugs and vaccines that are being researched and tested, which drugs are being repurposed to treat COVID-19, and which entities are leading and emerging for COVID-19 testing and treatment.
“As the COVID-19 pandemic progresses, a deluge of data is being generated every day and it is impossible for researchers to keep up,” said Gil Sadeh, CEO of Signals Analytics. “Most other platforms provide insights based on limited data sets or simple reference listings that require the user to input specific search parameters. The Signals Analytics platform on the other hand is designed to surface trends and actionable insights across a wide range of data sets to alleviate the burden researchers and analysts face as they look for clues that will speed up vaccine development and identify effective treatments. In the middle of this pandemic, every minute counts. We are proud to offer our COVID-19 Playbook to industry leaders, non-profits and government agencies to turn a very labor-intensive process filled with risk and uncertainty into something actionable and relevant that will speed up the end to this scourge.”
The COVID-19 Playbook includes dashboards such Drug Pipeline Overview, a Covid-19 Target and Modality Landscape, and Research Paper Assessment. In addition, users can set manual alerts through the Findings section to receive updates once per week.
On March 30, Signals Analytics will be sponsoring FiercePharma’s webinar called, “The Race to Develop a Vaccine” where the company will feature some early findings from its own analysis on the COVID-19 Playbook. For more information about the webinar and to register, click here.
With next-generation advanced analytics, Signals Analytics powers the future of market intelligence with the scale and speed of AI. The configurable data platform connects and classifies countless rich, external sources into unified contextual data, and augments analytic applications with unparalleled accuracy and scale. Patented machine learning, NLP and data automation technologies leapfrog traditional approaches of data collection and management to help organizations maximize the impact of advanced analytics and harness the power of external data to drive successful business outcomes. Business users, consumer and market insights teams and data & analytics organizations leverage the platform to surface powerful trends and predictive insights and benefit from business-ready applications and integrations of the data into their business intelligence environments. Trusted by an impressive roster of global brands including Procter & Gamble, Nestle, Johnson & Johnson, Bayer, Roche, Mars and others who experience higher sustainable growth, faster time to insight and other data-driven benefits, Signals Analytics is redefining the world of market intelligence. For more information visit www.signals-analytics.com